Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | VAXX | Class A common stock | Conversion of derivative security | +247K | +0.48% | 51.6M | Nov 15, 2021 | Direct | F1 | ||
transaction | VAXX | Class A common stock | Conversion of derivative security | +4.21M | 4.21M | Nov 15, 2021 | Held by United Biomedical Inc., Asia | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | VAXX | Series A preferred stock | Conversion of derivative security | -384K | -100% | 0 | Nov 15, 2021 | Class A common stock | 247K | Direct | F1 | |||
transaction | VAXX | Series A preferred stock | Conversion of derivative security | -6.55M | -100% | 0 | Nov 15, 2021 | Class A common stock | 4.21M | Held by United Biomedical Inc., Asia | F1, F2 |
Id | Content |
---|---|
F1 | Shares of preferred stock automatically converted into shares of Class A common stock upon closing of the Issuer's initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of preferred stock. |
F2 | Held by United Biomedical, Asia Inc. ("UBIA"). The Reporting Person, through a subsidiary, holds a majority equity interest in UBIA and may be deemed to be the beneficial owner of the shares held by UBIA. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by UBIA in which the Reporting Person has no pecuniary interest. |